What is the price target for IBIO stock?
12 analysts have analysed IBIO and the average price target is 5.47 USD. This implies a price increase of 246.46% is expected in the next year compared to the current price of 1.58.
IBIO INC (IBIO) Forecast, Price Target & Analyst Ratings
NASDAQ:IBIO • US4510337086
Current stock price
1.58 USD
-0.11 (-6.51%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for IBIO INC (IBIO).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- N/A
- Period
- Q3 / 2026
- EPS Estimate
- -$0.06
- Revenue Estimate
- 20.4K
Price Target Details & History
Consensus Price Target and Range
Mean target
$5.47
Upside
+ 246.46%
From current price of $1.58 to mean target of $5.47, Based on 12 analyst forecasts
Low
$4.24
Median
$5.10
High
$7.35
Price Target Revisions
1 Month
18.73%
3 Months
18.73%
Price Target Summary
12 Wall Street analysts provided a forecast for the next 12 months for IBIO. The average price target is 5.47 USD. This implies a price increase of 246.46% is expected in the next year compared to the current price of 1.58.
The average price target has been revised upward by 18.73% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
85.00%
IBIO was analyzed by 12 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about IBIO.
In the previous month the buy percentage consensus was at a similar level.
IBIO was analyzed by 12 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-04-09 | Chardan Capital | Maintains | Buy -> Buy |
| 2026-03-18 | Chardan Capital | Maintains | Buy -> Buy |
| 2026-03-03 | Jones Trading | Initiate | Buy |
| 2026-02-12 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-10-21 | Oppenheimer | Initiate | Outperform |
| 2025-10-17 | Leerink Partners | Initiate | Outperform |
| 2025-06-25 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-05-06 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-05-05 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-12-17 | LUCID CAPITAL MARKETS | Initiate | Buy |
| 2024-07-22 | Brookline Capital | Initiate | Buy |
| 2024-06-03 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-05-28 | Chardan Capital | Initiate | Buy |
| 2023-02-16 | JMP Securities | Downgrade | Market Outperform -> Market Perform |
| 2022-10-07 | Cantor Fitzgerald | Downgrade | Overweight -> Neutral |
| 2021-11-29 | JMP Securities | Initiate | Outperform |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- N/A
- Period
- Q3 / 2026
- EPS Estimate
- -$0.06
- Revenue Estimate
- 20.4K
- Revenue Q2Q
- N/A
- EPS Q2Q
- 86.95%
- Number of Analysts
- 8
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
-39.99%
EPS (1 Month)
0.00%
EPS (3 Months)
13.56%
Next Earnings Summary
The next earnings revenue estimate has been revised downward by 39.99% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates 2026 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | -100.00% | 225K | 400K 77.78% | 183.6K -54.10% | 122.4K -33.33% | 170.003K 38.89% | 255K 50.00% | 510K 100.00% | 510K | 44.37M 8,600.00% | 309.98M 598.63% | |
| EBITDA YoY % growth | -27.74M -12.44% | -15.705M 43.39% | -17.827M -13.51% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -28.77M -2.97% | -16.634M 42.18% | -18.602M -11.83% | -30.717M -65.13% | -46.823M -52.43% | -63.877M -36.42% | -59.435M 6.95% | -70.38M -18.42% | -104.04M -47.83% | -86.7M 16.67% | 24.48M 128.24% | |
| Operating Margin | N/A | -7,392.89% | -4,650.50% | -16,730.28% | -38,253.96% | -37,574.10% | -23,307.80% | -13,800.00% | -20,400.00% | -195.40% | 7.90% | |
| EPS YoY % growth | -115.20 -0.88% | N/A 93.44% | -1.92 74.60% | -0.32 83.10% | -0.30 8.99% | -0.40 -34.55% | -0.52 -30.88% | -0.45 13.73% | -0.43 4.55% | -0.22 47.62% | 0.07 131.82% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.06 86.95% | -0.06 87.03% | -0.09 21.18% | -0.08 15.00% | -0.08 -19.67% | -0.08 -20.33% |
| Revenue Q2Q % growth | 20.4K | 61.2K -69.40% | -100.00% | -100.00% | -100.00% | |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -7.286M -49.33% | -8.031M -54.51% | -9.18M -54.26% | -9.18M 2.81% | -9.18M -26.00% | -8.67M -7.95% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
21.49%
EPS Next 5 Year
12.05%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
-5.90%
Revenue Next 5 Year
20.11%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
IBIO INC / IBIO Forecast FAQ
What are the consensus estimates for IBIO stock next earnings?
The consensus EPS estimate for the next earnings of IBIO INC (IBIO) is -0.06 USD and the consensus revenue estimate is 20.40K USD.
What is the expected long term growth rate for IBIO stock?
The expected long term growth rate for IBIO INC (IBIO) is -5.9%.